

Annual Report 2022

- Established to address the need for a platform to facilitate knowledge exchange about regulatory systems and regulatory science in order to facilitate access to new, effective and safe therapies for patients.

Background

Regulatory Science Network Netherlands (RSNN)

Was founded in 2015 as a multistakeholder* platform

- **Bundling** expertise from Academia, Government, private Sector and patient organizations
- Knowledge **exchange** and **dissemination**
- To drive **research agenda's**

Mission

- To contribute to an **efficient** en **effective** regulatory system for medicines development, marketing authorisation, access and appropriate use.
 - **Platform** for regulatory science
 - **Involved** in all relevant regulatory science discussions
 - **Agenda-setting** for regulatory science
 - Knowledge **dissemination**

Ambition



Steering Committee 2022

Vereniging
Innovatieve
Geneesmiddelen

c B G
M E B



Universiteit Utrecht

Holland
BIO

lygature
pioneering medicine
together.



Sjaak Bot
Janssen Biologics



Marjon Pasmooij
Medicines
Evaluation Board
(CBG-MEB)



Peter Mol
UMCG/Medicines
Evaluation Board
(CBG-MEB)



Carla Vos
Vereniging van
Innovatieve
Geneesmiddelen
(VIG)



**Peter van Meer |
Vice-chair**
Medicines
Evaluation Board
(CBG-MEB)



**Marieke De
Bruin**
Utrecht
University



**Sophie Huiskes-
Berends**
Program Manager



**Pieter Stolk |
non-voting**
Lygature



Advisory Board 2022



- Francisco Hernandez, Pfizer, Chair
- Dr. Peter Bertens, VIG
- Carine Besselink, Eupati fellow
- dr. Helga Gardarsdottir, UU
- Prof. Dr. Joop van Gerven, Centrale Commissie Mensgebonden Onderzoek
- Marit Heblj, HollandBIO
- Dr. Jarno Hoekman, Utrecht University
- Dr. Agnes Kant, Lareb
- Prof. Dr. Aletta Kraneveld, Utrecht University
- Marlous Kooijman, FAST
- Dr. Larissa de Lannoy, PSC Patients Europe, patient advocate
- Evelien Minten, Medicines Evaluation Board (CBG-MEB)
- Connie van Oers, UniQure/RegNed
- Huib Scheijbeler, Bayer
- Lonneke Timmers, ZIN
- Aimad Torqui, Medicines Evaluation Board (CBG-MEB)
- Pauline Walstra, Astellas
- Just Weemers, Janssen
- Wieteke Wouters, HollandBIO



Focus 2021-2023

- **Increase visibility**
 - ❖ Assure prominent role of public partners in our activities
 - ❖ Strengthen dissemination of output of RSNN through partners and network
 - ❖ Strengthening online presence
- **Formulate leading regulatory science agenda**
 - ❖ Small and large themes selected through a rational selection process
 - ❖ National and international components
 - ❖ Gather input from various networks
- **Strengthen research activities**
 - ❖ Help fill in academic curricula
- **Build on expert meetings and** increase support for stakeholders for translating science to practice.
- **Increase input to public consultations** for EU policy documents on behalf of the RSNN.
- **Build new public-private platforms** around specific themes to support concrete research and dialogue



Activities 2022



Parallel session FIGON & EUFEPS
European medicines days



RSNN Annual
workshop



Expertmeeting regulator-
initiated studies



1. (inter)national visibility

- **Website**
- **Newsletter**
- **Linked-In**
- **Interview series**
- **Annual workshops**
 - 2018 Sensible label
 - 2019 Trial innovation
 - 2020 EMA
 - 2021 Convergence
 - 2022 Patient preferences
- **Rapid Response Expert Meetings**
 - Regulator-initiated studies
- **FIGON/Dutch Medicine Days**
 - Academic drug development

4. Building on expertmeetings

- **Follow-up activities**
 - SIG ATMPs

2. Regulatory science agenda

- **FAST**
 - multi-stakeholder model
 - Schil I (Helpdesk), Schil II (Ronde tafel), Schil III (Denktank)
 - Pandemic Preparedness
 - RMT, PV, ATMPs, drug repurposing

3. Catalyze research activities


- **Reports**
 - Expertmeeting regulator-initiated studies
 - Annual workshop Patient preferences
- **FAST**
 - Pandemic Preparedness
 - RMT, PV, ATMPs, drug repurposing
- **Support masterstudents**

5. Increase input Public consultations

- **EMA consultations**
 - Metadata
 - Data quality

6. Build new PP platforms

- **New sponsor**
 - Bayer
- **SIG ATMPs**



* Livestream included



RSNN Regulatory Science Network Netherlands

Thank you!

**Vereniging
Innovatieve
Geneesmiddelen**

C B G
M E B



**Holland
BIO**



Universiteit Utrecht

lygature
pioneering medicine.
together.